Lupus anticoagulant interference in activated protein C resistance testing: in vitro phenomenon or in vivo pathophysiologic effect?
Shen YM, Cimo ML, Bai Y, Frenkel E, Sarode R Clin. Appl. Thromb. Hemost. 2011 Nov-Dec 17 6 E190-5
The paradoxical effect of bevacizumab in the therapy of malignant gliomas.
Thompson EM, Frenkel EP, Neuwelt EA Neurology 2011 Jan 76 1 87-93
Thrombohemorrhagic defects associated with malignancy
Frenkel EP, Bick RL Lippincott Williams and Wilkins 2002 3rd Edition 265-282
Thrombocytopenia and thrombocytosis in: disorders of thrombosis and hemostasis: clinical and laboratory practice
Frenkel EP Lippincott Williams and Wilkins 2002 3rd Edition 91-115
Cobalamin Profiles in patients after urinary diversion
Sagalowsky AI, Frenkel EP J Urol 2002 167 1696-1700
Aberrant promoter methylation profile of prostate cancers and its relationship to clinical pathological features
Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zochbauer-Muller S, Farinas AJ, Minna JD, McConnell J, Frenkel EP, Gazdar Af Clin Cancer Research 2002 8 514-519
Enhanced transgene expression in androgen independent prostate cancer gene therapy by taxane chemotherapeutic agents
Li Y, Okegawa T, Lombardi DP, Frenkel EP, Hsieh JT J Urol 2002 167 339-346